Genostim Performance Labs · Prepared by the Pet Jet LLC Advisory Consortium
Lead consortium entity; DTC growth, digital infrastructure, and consumer brand strategy
B2B commercial architecture, manufacturing operations, and supply chain strategy
Market intelligence, competitive analysis, and technology ecosystem integration
International market development, strategic partnership identification, and investor relations
Conservative Base Case
Human · Pet · Collagen B2B
3-yr vest, zero cash fees
Genostim Performance Labs stands at a rare strategic inflection point. Built on 20+ years of proprietary peptide research by Lauriston Crockett III, the company has developed a science-first collagen platform applicable across three entirely separate, multi-billion-dollar markets — each with its own regulatory pathway, distribution infrastructure, and end customer.
US collagen peptide market: $2.5B in 2025, 12.9% CAGR → $4.9B by 2030. Governed by DSHEA. Channels: DTC e-commerce, Amazon, HCP, specialty retail. Y5 target: $22.5M.
US pet supplement market: $4.76B in 2025, 10% CAGR. Governed by AAFCO. Channels: Vet clinics, DTC/Chewy, PetSmart, Petco. Y5 target: $20.0M.
US collagen ingredient market: $2.7B in 2025, ~8% CAGR. Governed by GRAS. Channels: F&B manufacturers, nutraceutical brands, cosmetics formulators. Y5 target: $40.5M.
The US collagen peptide supplement market is valued at approximately $2.5 billion in 2025, expanding at a 12.9% CAGR with a projected value of $4.9 billion by 2030. The five dominant players (Vital Proteins/Nestle, Ancient Nutrition, NeoCell, Sports Research, and Momentous) collectively control approximately 65% of market share — leaving meaningful white space for a science-differentiated challenger brand.
Genostim's differentiation: The 3-Layer Regeneration System — BUILD (Collagen Peptides) + ABSORB (Probiotics) + ACTIVATE (ISOTIDE™ Peptides) — combined with 28 bioactive growth factors, 18 amino acids, and a pinocytosis delivery mechanism.
Positioning: "This isn't just collagen. This is collagen that knows what to do."
Channel Strategy:
The US pet supplement market reached approximately $4.76 billion in 2025, expanding at 10% annually, driven by pet humanization. Primary competitors — Zesty Paws, Nutramax (Cosequin), VetriScience, and PetHonesty — compete primarily on price and retail shelf placement. None has a proprietary peptide delivery mechanism comparable to the ISOTIDE™ platform.
Pet supplements are governed by AAFCO — not FDA dietary supplement law. Products must be registered state-by-state (3–9 months per state). NASC Quality Seal is effectively required for serious vet channel distribution. NASC certification is a Year 1 priority with an estimated 6–9 month implementation timeline.
The US collagen ingredient market — serving food and beverage manufacturers, cosmetics formulators, and pharmaceutical companies — is valued at approximately $2.7 billion in 2025. The F&B segment accounts for 57% of this market. The global market is dominated by five suppliers: Rousselot (PB Leiner parent), Gelita AG, Nitta Gelatin, and Chinese manufacturers.
Genostim's competitive differentiation rests on three pillars: Made in USA / Texas sourcing, grass-fed and traceable supply chain, and a bioactive profile (28 growth factors, proprietary peptide processing) that generic commodity hydrolysate cannot replicate.
B2B sales cycles of 6–18 months from first contact to purchase order. Capital investment required for SQF, FSMA compliance, and COAs.
Model reaches EBITDA break-even in Year 3. Year 1 deficit funded through consortium co-investment syndication of $500K–$2M.
Improving to 35% at scale through manufacturing efficiency across all three streams.
DTC-heavy in Years 1–2, normalizing to 20% by Year 3 as organic traffic and brand equity build.
Scales proportionally with revenue; shared infrastructure across streams where possible.
Held constant to fund the human clinical trial program and formulation development for pet and B2B streams.
Year 1 deficit of $0.8M funded through consortium co-investment syndication of $500K–$2M. No external equity raise assumed in base case.
Model reaches EBITDA break-even in Year 3 and positive cumulative cash position by mid-Year 3.
Grass-fed, US-sourced collagen hydrolysate providing the structural amino acid substrate — 18 amino acids including high concentrations of glycine, proline, and hydroxyproline — for connective tissue synthesis.
A probiotic complex designed to optimize the gut environment for collagen peptide absorption. Improves bioavailability of the peptide fraction reaching systemic circulation.
The proprietary differentiated element. ISOTIDE™ peptides function through a pinocytosis delivery mechanism — delivering 28 identified bioactive growth factors directly to target tissues.
Clean. Clinical. Powerful.
DSHEA governs all human dietary supplement marketing. Collagen is a pre-existing ingredient — no NDI notification required. Structure/function claims permitted but require: (1) claim substantiation file, (2) FDA notification within 30 days, (3) mandatory disclaimer on all materials.
Pet supplements are governed by AAFCO — not FDA dietary supplement law. Every state requires a separate product registration (30 days to 9 months per state). A 50-state registration program requires 18–24 months to complete fully. NASC Quality Seal is effectively required for serious vet channel distribution. NASC certification is a Year 1 priority (6–9 month timeline).
Collagen hydrolysate is eligible for GRAS status. Voluntary FDA GRAS notification recommended for premium B2B positioning. Additional requirements: SQF certification (manufacturing), FSMA compliance (ingredient suppliers), Kosher/Halal certification, NSF certification for pharmaceutical-grade customers. Prioritize SQF and FSMA in Year 1 as gating criteria for first anchor contracts.
A proprietary clinical study is the most durable competitive moat available to a science-first supplement brand. It enables structure/function claim substantiation at a standard no competitor can quickly replicate, unlocks HCP endorsement at scale, supports premium pricing, and creates category authority in earned media.
All human clinical trials must be registered on ClinicalTrials.gov before the first participant is enrolled. Competitive bidding across 2–3 CROs recommended. Budget should include 15–20% contingency for protocol amendments and participant retention challenges.
An honest, unvarnished assessment of competitive position across all three revenue streams. Green represents genuine structural advantages. Red represents real risks and gaps the consortium's program is designed to address.
The science underlying Genostim Performance Labs is proprietary, patentable, and commercially differentiated in ways that standard hydrolyzed collagen products are not. Developed over 20+ years by Lauriston Crockett III.
Genostim's organic traffic value is approximately $275/month vs. BodyBio's $224,911/month — an 818× deficit. The Information Network (TIN) brings custom AI tooling trained on Genostim's proprietary science library, Crockett's Peptide Effect series, and competitive keyword data to produce a content engine generating topical authority across peptide, anti-aging, cellular health, and pet wellness categories.
What the Consortium Brings: Growth Strategy · Digital Infrastructure · Regulatory Navigation · Clinical Trial Design · B2B Channel Development · Financial Architecture · Brand Architecture
15–20% combined consortium stake, structured as restricted units
3-year vest with 1-year cliff
Zero — pure advisory-for-equity alignment; no retainer, no hourly billing, no project fees
$500K – $2M syndication support from consortium network
All three revenue streams — Human Peptides, Pet Peptides, and Collagen B2B — from Day 1
90-day mutual fit / performance review at 90 days post-close
Q1–Q2 2026 · Brand refresh for Genostim® and TGFL®. DTC infrastructure rebuild. Technical SEO audit and remediation. Regulatory counsel engagement (DSHEA/GHK-Cu). NASC membership application. SQF certification initiation.
Q3–Q4 2026 · 50-topic content pillar/cluster strategy live. 20+ editorial placements in health, wellness, and clinical publications. Amazon A+ content and review velocity program. First B2B anchor contracts signed. Pilot clinical study initiated.
Year 2 · Chewy listing + PetSmart pilot for TGFL®. HCP channel launch with clinical dossier. 5–8 active B2B accounts. Full RCT underway. Affiliate and influencer programs at scale.
Year 3 · National specialty retail rollout (Sprouts, Whole Foods, Vitamin Shoppe). 20+ B2B accounts; broker network in 3 regions. Clinical trial publication. $25.5M combined revenue target.
Year 5 · $83M combined revenue. 75,000+ human subscribers. Full multi-channel pet penetration. 1.5% B2B TAM penetration. Pharmaceutical-grade qualification in progress.
Establish the consortium board advisory structure (Day 1–30)
GHK-Cu / growth factor label review — critical priority (Day 1–30)
Full audit of genostim.com (Day 1–14)
For TGFL® pet brand (Day 1–30)
For Year 1 pilot clinical study (Day 30–60)
For B2B ingredient supply (Day 30–90)
Operational tracking for all three streams (Day 30)
The Pet Jet LLC Advisory Consortium will begin immediate execution on the highest-priority legal, regulatory, and growth items, while building the operational foundation for the three business streams.
This proposal is prepared on a confidential basis for Genostim Performance Labs. All market data is sourced from publicly available industry research and is believed to be accurate as of April 2026. Revenue projections are forward-looking estimates subject to market conditions, regulatory developments, and execution factors.
For questions or to initiate the engagement, contact the Pet Jet LLC Advisory Consortium through your designated consortium liaison.
AI-Powered Growth & Sales Acceleration Program